Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2020

View Archived Issues

Evaluating the clinical significance of KIAA1199 expression in locally advanced gastric cancer

S166 phosphorylation is essential for cell death and inflammation in RIPK1-dependent diseases

Study of de novo missense EIF2K2 variants as responsible for neurological disorders

Insulin cuts both ways in vasculature

Transcriptomic insights into Parkinson's disease

FDA approves IND application for CAN-04

Successful completion of phase II study of SPI-1005 in bipolar disorder

Phase III trial of Solosec for trichomoniasis meets primary endpoint

First COVID-19 patient enrolled in ongoing phase III study of AR-301

Eli Lilly and Company patents new KRAS G12C inhibitors

Viriom initiates phase II study of long-acting injectable VM-1500A

Intarcia Therapeutics discloses new amylin analogues

New SSTR5 agonists presented by Heptares Therapeutics

CytoDyn requests compassionate use of leronlimab for COVID-19

Takeda Pharmaceutical synthesizes mTOR inhibitors

Shanghai Ennova Biopharmaceutical identifies new TRK inhibitors

Allakos reports interim data from open-label extension study of antolimab

GDC-9545, a third-generation ER-alpha ligand with improved potency

Phase III data for HL-301 in acute bronchitis

Novel ADPRHL2 gene mutation linked to newly identified neurological syndrome

First preclinical results presented for XmAb bispecific antibody AMG-509

Sphingolipid may be new schizophrenia drug target

Promising topline data reported from pivotal trial of Libtayo in advanced BCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...